Viennese Ribbon Biolabs closes €18m Series A financing

New investors Lansdowne Partners, Helicase Venture as well as several undisclosed investors participated in the Series A round. Existing investors IST cube and tecnet equity also joined in the investor consortium. 

Ribbon Biolabs said it will use the proceed to establish commercial-scale DNA synthesis in Europe and to expand its operations into the US. Ribbon Biolabs’ DNA synthesis technology uses an innovative approach integrating combinatorial optimisation algorithms to guide the automated enzymatic assembly of DNA

The company was founded in 2018 in Vienna to redefine the potential of synthetic DNA. The technology addresses the growing market need for synthetic DNA of sub-genomic size, up to 20 Kbp, a component for developments in biopharmaceutical research and synthetic biology.